Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03617718 · ClinicalTrials.gov registry record · Phase 1
Project 2 Airway Potential Hydrogen (pH) in Asthma
A Phase 1 study, sponsored by Case Western Reserve University.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT03617718 is a Phase 1 study that has completed, run by Case Western Reserve University. The registered enrollment target is 74 participants.
The verdict
NCT03617718, a Phase 1 study, has completed, sponsored by Case Western Reserve University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study is testing a non invasive way to measure airway pH in individuals with Asthma and Cystic Fibrosis using a new inhaled drug. The airway pH will help health care providers in creating tailored treatment plans for individuals suffering from these specific conditions.
Interventions
- DRUG Glycine Buffer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2025-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03617718
The ClinicalTrials.gov registry entry for NCT03617718 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glycine Buffer is the first listed.
NCT03617718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03617718 about?
NCT03617718 is a clinical study titled "Project 2 Airway Potential Hydrogen (pH) in Asthma". This study is testing a non invasive way to measure airway pH in individuals with Asthma and Cystic Fibrosis using a new inhaled drug. The airway pH will help health care providers in creating tailored treatment plans for individuals suffering from these specific conditions.
What is the current status of trial NCT03617718?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2018-11-01. Estimated completion is 2025-07-16.
What interventions are being tested in trial NCT03617718?
The interventions under investigation include: Glycine Buffer (DRUG).
Who is sponsoring clinical trial NCT03617718?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.